JP2010539101A5 - - Google Patents

Download PDF

Info

Publication number
JP2010539101A5
JP2010539101A5 JP2010524261A JP2010524261A JP2010539101A5 JP 2010539101 A5 JP2010539101 A5 JP 2010539101A5 JP 2010524261 A JP2010524261 A JP 2010524261A JP 2010524261 A JP2010524261 A JP 2010524261A JP 2010539101 A5 JP2010539101 A5 JP 2010539101A5
Authority
JP
Japan
Prior art keywords
compound
formula
salt
converted
converting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010524261A
Other languages
English (en)
Japanese (ja)
Other versions
JP5202635B2 (ja
JP2010539101A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/076002 external-priority patent/WO2009036161A1/en
Publication of JP2010539101A publication Critical patent/JP2010539101A/ja
Publication of JP2010539101A5 publication Critical patent/JP2010539101A5/ja
Application granted granted Critical
Publication of JP5202635B2 publication Critical patent/JP5202635B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010524261A 2007-09-11 2008-09-11 インテグラーゼ阻害剤の調製のためのプロセスおよび中間体 Expired - Fee Related JP5202635B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97139507P 2007-09-11 2007-09-11
US60/971,395 2007-09-11
PCT/US2008/076002 WO2009036161A1 (en) 2007-09-11 2008-09-11 Process and intermediates for preparing integrase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013024589A Division JP2013129659A (ja) 2007-09-11 2013-02-12 インテグラーゼ阻害剤の調製のためのプロセスおよび中間体

Publications (3)

Publication Number Publication Date
JP2010539101A JP2010539101A (ja) 2010-12-16
JP2010539101A5 true JP2010539101A5 (enExample) 2012-01-26
JP5202635B2 JP5202635B2 (ja) 2013-06-05

Family

ID=39887255

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010524261A Expired - Fee Related JP5202635B2 (ja) 2007-09-11 2008-09-11 インテグラーゼ阻害剤の調製のためのプロセスおよび中間体
JP2013024589A Withdrawn JP2013129659A (ja) 2007-09-11 2013-02-12 インテグラーゼ阻害剤の調製のためのプロセスおよび中間体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013024589A Withdrawn JP2013129659A (ja) 2007-09-11 2013-02-12 インテグラーゼ阻害剤の調製のためのプロセスおよび中間体

Country Status (20)

Country Link
US (4) US20090099366A1 (enExample)
EP (1) EP2190804B1 (enExample)
JP (2) JP5202635B2 (enExample)
KR (1) KR101488550B1 (enExample)
CN (1) CN101821223B (enExample)
AP (1) AP2785A (enExample)
AR (1) AR068403A1 (enExample)
AU (1) AU2008298943B2 (enExample)
BR (1) BRPI0816694A2 (enExample)
CA (1) CA2698245C (enExample)
CO (1) CO6270255A2 (enExample)
EA (1) EA019431B1 (enExample)
ES (1) ES2562080T3 (enExample)
MX (1) MX2010002783A (enExample)
NZ (1) NZ583647A (enExample)
PT (1) PT2190804E (enExample)
TW (1) TWI419867B (enExample)
UA (1) UA101956C2 (enExample)
WO (1) WO2009036161A1 (enExample)
ZA (1) ZA201002066B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK2662004A3 (sk) * 2002-11-20 2005-06-02 Japan Tobacco, Inc. Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz
EP1976517A1 (en) * 2005-12-30 2008-10-08 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2007102499A1 (ja) 2006-03-06 2007-09-13 Japan Tobacco Inc. ４－オキソキノリン化合物の製造方法
ES2531190T3 (es) 2006-03-06 2015-03-11 Japan Tobacco Inc Método para producir un compuesto de 4-oxoquinolina
WO2008033836A2 (en) 2006-09-12 2008-03-20 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US20100331331A1 (en) * 2007-06-29 2010-12-30 Therapeutic Compositons And Use Thereof Therapeutic compositions and the use thereof
AR067184A1 (es) * 2007-06-29 2009-09-30 Gilead Sciences Inc Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
WO2011004389A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
AU2013296289B2 (en) 2012-08-03 2017-10-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
CZ304984B6 (cs) * 2012-10-12 2015-03-11 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy elvitegraviru
CZ304983B6 (cs) * 2012-10-12 2015-03-11 Zentiva, K.S. Způsob výroby a nové intermediáty syntézy elvitegraviru
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
ES2859102T3 (es) 2013-07-12 2021-10-01 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
NO2865735T3 (enExample) 2013-07-12 2018-07-21
NO2717902T3 (enExample) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
KR20190057158A (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
CN111733133B (zh) * 2020-07-22 2020-12-01 华夏源(上海)生命科技有限公司 一种促进表皮干细胞分化和生长的方法
CN111944761B (zh) * 2020-08-23 2021-03-26 泉州伟业生物医学科技有限公司 促进表皮干细胞分化和生长的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1564210A (en) * 1925-12-08 Obin d
DE3501247A1 (de) * 1985-01-16 1986-07-17 Bayer Ag, 5090 Leverkusen Aminoacrylsaeure-derivate
MXPA03005338A (es) 2000-12-14 2003-10-06 Procter & Gamble Etapa de ciclizacion en el procedimiento de elaboracion de quinolonas y naftiridinas.
TW200300349A (en) 2001-11-19 2003-06-01 Sankyo Co A 4-oxoqinoline derivative
AU2003235447A1 (en) * 2002-05-31 2003-12-19 Banyu Pharmaceutical Co., Ltd. Method of substituent introduction through halogen-metal exchange reaction
US6803469B2 (en) * 2002-08-05 2004-10-12 The Procter & Gamble Company Process for preparing quinolone antibiotic intermediates
TW200409759A (en) 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols
SK2662004A3 (sk) * 2002-11-20 2005-06-02 Japan Tobacco, Inc. Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz
EP1582523A1 (en) 2004-04-02 2005-10-05 Ludwig-Maximilians-Universität München Method of preparing organomagnesium compounds
EP1582524B1 (en) 2004-04-02 2008-08-13 Ludwig Maximilians Universität Method of preparing organomagnesium compounds
US7531554B2 (en) 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP1758581A1 (en) 2004-05-21 2007-03-07 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
WO2007063869A1 (ja) 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
ES2531190T3 (es) 2006-03-06 2015-03-11 Japan Tobacco Inc Método para producir un compuesto de 4-oxoquinolina
WO2007102499A1 (ja) 2006-03-06 2007-09-13 Japan Tobacco Inc. ４－オキソキノリン化合物の製造方法
TW200811153A (en) * 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
WO2008033836A2 (en) * 2006-09-12 2008-03-20 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US20100331331A1 (en) * 2007-06-29 2010-12-30 Therapeutic Compositons And Use Thereof Therapeutic compositions and the use thereof
AR067184A1 (es) * 2007-06-29 2009-09-30 Gilead Sciences Inc Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa

Similar Documents

Publication Publication Date Title
JP2010539101A5 (enExample)
JP5221544B2 (ja) インテグラーゼ阻害剤を調製するためのプロセスおよび中間体
JP2010503694A5 (enExample)
JP5734207B2 (ja) 亜鉛アミド類の製造及び使用
CA3005738C (en) 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
JP2010500343A5 (enExample)
JP2010540477A5 (enExample)
JP2007260659A5 (ja) 液相反応用のポリシラン担持遷移金属触媒
JP2013505273A5 (enExample)
JP2011524871A5 (enExample)
JP2013538208A (ja) 改良されたルフィナミド調製プロセス
JP2018506541A5 (enExample)
JP2006526587A5 (enExample)
US20200024220A1 (en) Method for preparing 2-aryl malonamide and applications thereof
TW201040152A (en) Method for preparing ascorbic acid derivatives
JP2013530948A5 (enExample)
RU2013110311A (ru) Синтез соединений тиазолидиндиона
JP6289470B2 (ja) 置換ガンマラクタムの合成方法
JPS63179856A (ja) キノロンカルボン酸誘導体の製造方法並びにその中間体
CN103951632A (zh) 2,2,7-三氟-2h-1,4-苯并噁嗪-3(4h)-酮类化合物的制备方法
JP6723817B2 (ja) （トリフルオロメチル）マロン酸エステルの製造方法
JP2008500316A5 (enExample)
JP2010523620A5 (enExample)
TW200538431A (en) The method of synthesizing the compounds with the functional group CHF2C(O)- or CHFC(O)
JP2011074063A5 (enExample)